Rapamycin and human longevity among kidney transplant recipients surviving the first year

Coverage, in order

1. 7d ago
   first GeroScience indie study observational

   Rapamycin and human longevity among kidney transplant recipients surviving the first year

   Rapamycin, an mTOR inhibitor, continues to be investigated for hypothesized physiological, disease prevention, and longevity benefits, but few studies have been conducted in humans. Using US national organ transplant registry data, one of the largest real-world datasets examining chronic rapamycin…

2. 5d ago
   
   Rapamycin News obscure

   Rapamycin and human longevity among kidney transplant recipients surviving the first year (paper 5th November 2026)

   SpringerLink Rapamycin and human longevity among kidney transplant recipients surviving... Rapamycin, an mTOR inhibitor, continues to be investigated for hypothesized physiological, disease prevention, and longevity benefits, but few studies have been conducted in humans. Using US national organ…

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.